Press release
Moderate Psoriasis Market Growth, Applications, Innovations and Business Outlook by 2034
Moderate Psoriasis Market
Psoriasis is a chronic autoimmune skin condition that accelerates the life cycle of skin cells, leading to red, scaly plaques that cause itching, discomfort, and psychosocial distress. Moderate psoriasis represents a significant disease burden-it is more severe than mild cases yet not as extensive as severe psoriasis, making treatment strategies diverse and evolving.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71341
Management of moderate psoriasis historically relied on topical corticosteroids, phototherapy, and conventional systemic drugs. However, the introduction of biologics, biosimilars, and targeted oral small molecules such as JAK and TYK2 inhibitors is revolutionizing the treatment landscape. With increasing prevalence, growing awareness, and advances in personalized dermatology, the global moderate psoriasis market is set for strong expansion through 2034.
Market Overview
• Market Size 2024: USD 12.5 billion
• Forecast 2034: USD 20 billion
• CAGR (2025-2034): 5.1%
The market is projected to grow steadily, driven by the adoption of biologics, expansion of biosimilars, and rising use of small-molecule oral therapies. Digital health platforms for remote skin monitoring are also supporting long-term patient engagement and adherence.
Leading Players include: Novartis, AbbVie, Eli Lilly, Johnson & Johnson, Amgen, Bristol Myers Squibb, Pfizer, UCB, and Sun Pharma.
Segmentation Analysis
By Product
• Biologics (TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibitors)
• Small Molecules (JAK inhibitors, TYK2 inhibitors)
• Conventional Systemics (Methotrexate, Cyclosporine, Acitretin)
• Topical Therapies (Corticosteroids, Vitamin D Analogs, Calcineurin Inhibitors)
• Biosimilars
• Supportive Care Medications
By Platform
• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies
By Technology
• Biologic & Biosimilar Drug Development Platforms
• Small Molecule Innovation (JAK/TYK2 inhibitors)
• Digital Dermatology & AI Skin Monitoring
• Precision Medicine & Biomarker Diagnostics
By End Use
• Hospitals & Dermatology Clinics
• Specialty Immunology Centers
• Academic & Research Institutes
• Homecare Settings
By Application
• Plaque Psoriasis
• Guttate Psoriasis
• Pustular Psoriasis
• Other Moderate Psoriasis Types
Summary:
Biologics dominate the market, especially IL-17 and IL-23 inhibitors, while TYK2 inhibitors are emerging as strong oral alternatives. Biosimilars are improving access and affordability globally, particularly in emerging markets.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71341/moderate-psoriasis-market
Regional Analysis
North America
• Largest market due to FDA approvals of advanced biologics and TYK2 inhibitors, strong reimbursement support, and high disease awareness.
• U.S. leads in adoption of IL-23 inhibitors and digital dermatology tools.
Europe
• Strong market share with EMA-approved biologics, widespread biosimilar penetration, and robust patient registries.
• Germany, France, and the UK drive regional adoption.
Asia-Pacific
• Fastest-growing region due to rising autoimmune disease burden, improving healthcare infrastructure, and biosimilar introductions in China, India, and Japan.
Middle East & Africa
• Gradual growth with expanding dermatology facilities but limited biologic access due to high costs.
Latin America
• Moderate growth with Brazil and Mexico leading adoption of biologics and biosimilars.
Regional Summary:
While North America and Europe dominate the market today, Asia-Pacific is projected to post the fastest CAGR through 2034, driven by demographics, healthcare expansion, and biosimilar adoption.
Market Dynamics
Key Growth Drivers
• Rising prevalence of psoriasis worldwide.
• Increasing adoption of biologics, JAK inhibitors, and TYK2 inhibitors.
• Expansion of biosimilars improving affordability.
• Growing role of digital dermatology platforms for disease management.
Key Challenges
• High costs of advanced biologics and small-molecule therapies.
• Variability in patient response and relapse risk.
• Limited access to specialty care in low-income regions.
Latest Trends
• FDA/EMA approvals of next-generation IL-23 inhibitors and TYK2 inhibitors.
• Growth of biosimilars expanding global patient access.
• Adoption of AI-driven skin monitoring apps and teledermatology.
• Increasing research into combination regimens for better efficacy and durability.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71341
Competitor Analysis
Major Players in the Market:
• Novartis - Cosentyx (IL-17 inhibitor) driving strong adoption.
• AbbVie - Skyrizi (IL-23 inhibitor) and Humira remain market leaders.
• Eli Lilly - Taltz (IL-17 inhibitor) continues to grow in share.
• Johnson & Johnson - Tremfya (IL-23 inhibitor) and Stelara (IL-12/23 inhibitor) dominate key segments.
• Amgen - Expanding biosimilar footprint globally.
• Bristol Myers Squibb - Innovator with deucravacitinib (TYK2 inhibitor).
• Pfizer - Expanding JAK inhibitor therapies.
• UCB - Dermatology-focused biologic portfolio.
• Sun Pharma - Strong in generics and biosimilar dermatology solutions.
Competitive Dynamics:
The market is highly competitive, with AbbVie, Novartis, and Eli Lilly leading biologics, while Bristol Myers Squibb pushes growth in TYK2 inhibitors. Biosimilars are intensifying competition, especially in Europe and Asia-Pacific.
Conclusion
The moderate psoriasis market is undergoing rapid transformation as biologics, TYK2 inhibitors, and biosimilars expand therapeutic options. Despite challenges of affordability and variable patient response, the future outlook through 2034 is highly positive.
Key Takeaways:
• Market projected to grow at a CAGR of 5.1% (2025-2034).
• IL-17 and IL-23 inhibitors dominate, while TYK2 inhibitors are fastest-growing.
• North America and Europe lead today, but Asia-Pacific posts fastest growth.
• Digital health platforms and biosimilars are reshaping patient access and affordability.
• Competition is focused on biologics, small-molecule innovation, and precision dermatology solutions.
Overall, the moderate psoriasis market presents strong opportunities for pharma leaders, biotech innovators, and digital health companies to improve treatment outcomes and expand global access.
This report is also available in the following languages : Japanese (中等度乾癬市場), Korean (중등도 건선 시장), Chinese (中度牛皮癣市场), French (Marché du psoriasis modéré), German (Markt für mittelschwere Psoriasis), and Italian (Mercato della psoriasi moderata), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71341/moderate-psoriasis-market#request-a-sample
Our More Reports:
Cutaneous Squamous cell Carcinoma Market
https://exactitudeconsultancy.com/reports/71380/cutaneous-squamous-cell-carcinoma-market
Papulopustular Rosacea Market
https://exactitudeconsultancy.com/reports/71388/papulopustular-rosacea-market
Prurigo Nodularis Market
https://exactitudeconsultancy.com/reports/71390/prurigo-nodularis-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Moderate Psoriasis Market Growth, Applications, Innovations and Business Outlook by 2034 here
News-ID: 4163680 • Views: …
More Releases from Exactitude Consultancy
Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…
Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…
Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…
PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for TYK2
Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline 2025: FDA Updates, Therapy Innovati …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
The Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical…
Emerging Trends Influencing The Growth Of The Kinase Inhibitors Market: Advances …
The Kinase Inhibitors Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
How Big Is the Kinase Inhibitors Market Size Expected to Be by 2034?
The kinase inhibitors market will grow from $62.75 billion in 2024 to $67.57 billion in 2025, reflecting a CAGR of 7.7%. Growth…
TYK2 Kinase Inhibitors Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, …
(Albany, USA) "TYK2 Kinase Inhibitors Pipeline Insight, 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the TYK2 Kinase Inhibitors Therapeutics Market.
As per DelveInsight's assessment, about 15+ prominent pharma and biotech giants are working on 15+ drugs in the TYK2 Kinase Inhibitors pipeline landscape globally.
The TYK2 Kinase Inhibitors pipeline report provides a detailed description of the pipeline drugs, including the mechanism…
Key Trends Shaping the Future Kinase Inhibitors Market From 2025-2034: Advances …
What Is the Estimated Market Size and Growth Rate for the Kinase Inhibitors Market?
In the past few years, there has been a significant increase in the market size of kinase inhibitors. This market is set to expand from $62.75 billion in 2024 to $67.57 billion in 2025, marking a compound annual growth rate (CAGR) of 7.7%. The historical growth can be linked to numerous factors including the rise in cancer…
Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Assessment, 2023 Updates | In-depth …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Tyrosine Kinase 2 (TYK2) Inhibitors pipeline constitutes 15+ key companies continuously working towards developing 15+ Tyrosine Kinase 2 (TYK2) Inhibitors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Tyrosine Kinase 2 (TYK2) Inhibitors Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and…
Non Receptor Tyrosine Protein Kinase TYK2 Market Share Will Gain Hugh Momentum b …
In recent years, the Global Non Receptor Tyrosine Protein Kinase TYK2 Market has witnessed significant growth and is expected to continue to do so during the forecast period 2023-2030. This report aims to provide a comprehensive analysis of the market's critical aspects, including its strengths, weaknesses, opportunities, and threats. With the help of SWOT and Porter's Five Forces analysis, we will explore the different players operating in the market and…
